SET and chronic myelogenous leukemia, BCR-ABL1 positive: FTY720 treatment also inhibits epithelial‐to‐mesenchymal transition (EMT) by affecting SET/PP2A/c‐Myc/NDRG1/Snail signaling, and restore sensitivity to standard treatments such as cisplatin in lung cancer cells, and imatinib in chronic myeloid leukemia cells harboring resistant mutations.16, 72, 73 COG112 is a specific cell‐penetrating peptide.